The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Bowel cancer is the 2nd most common cause of cancer death in Australia. Rectal cancer represents 40% of these, and is more common in the elderly who are frequently unable to tolerate chemoradiation therapy. The Mutated in Colorectal Cancer gene (MCC) could become a predictor to chemoradiotherapy in up to 30% of these patients. A defective MCC in tumours can predict a good response to this treatment. Our project will potentially identify patients that are more sensitive to chemoradiotherapy and l ....Bowel cancer is the 2nd most common cause of cancer death in Australia. Rectal cancer represents 40% of these, and is more common in the elderly who are frequently unable to tolerate chemoradiation therapy. The Mutated in Colorectal Cancer gene (MCC) could become a predictor to chemoradiotherapy in up to 30% of these patients. A defective MCC in tumours can predict a good response to this treatment. Our project will potentially identify patients that are more sensitive to chemoradiotherapy and lead to a personalized treatment of rectal cancer.Read moreRead less
A New Therapeutic Monoclonal Antibody Targeting CD302 In Acute Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
This project will develop a new antibody treatment for Acute Myeloid Leukaemia. Antibody treatments help the body to attack the leukaemia using its immune system. The prognosis of this leukaemia is poor. Our current treatments use high dose chemotherapy and sometimes a stem cell transplant. Many patients cannot have the current therapy due to their age or other medical problems. A new antibody therapy may be used on its own or with other therapies to help more patients achieve remission.
The Regulation Of Monocyte Derived Dendritic Cells (moDCs) During Allograft Rejection
Funder
National Health and Medical Research Council
Funding Amount
$110,218.00
Summary
Islet transplantation can cure type 1 diabetes, but the required drugs for immunosuppressing graft rejection have side effects. Therefore understanding how immune rejection occurs so that we can suppress in a more discreet selective way is our goal. A type of cell that is prominent during graft rejection is the monocyte derived dendritic cell. We propose that this cell is critical for orchestrating immune responses during rejection. Therefore we wish to determine how such cells are controlled.
Defining The Role Of Kidney CD103+ Dendritic Cells In Kidney Disease For Potential Therapies
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
Chronic Kidney Disease (CKD) is a major cause morbidity. Dendritic cells (DCs) play a central role in the development and progression of CKD. This research is based on our recent novel finding in which CD103+ DCs have been defined, for the first time, as a major subset of kidney DCs, and shown to be pathogenic in many kidney diseases. This research will further investigate the role of CD103+ DCs in various types of CKD and aim to develop therapeutic strategies to target CD103+ DCs to treat CKD.
Functional Aspects Of CD52 Signalling In Immune Regulation
Funder
National Health and Medical Research Council
Funding Amount
$133,351.00
Summary
Autoimmune disease, such as Rheumatoid arthritis, Type 1-Diabetes, Lupus and Multiple Sclerosis, is caused by disruptions in the normal control of the immune system. A type of cell called a regulatory T-cell can prevent these damaging immune reactions. However, we do not know how T-cells do this. CD52 is a protein found on the surface of T-cells. Our preliminary work shows that CD52 also suppresses these damaging immune responses. This project researches how CD52 influences the immune system.
Adaptive Immunity To Non-typeable H. Influenzae In Children With Bronchiectasis
Funder
National Health and Medical Research Council
Funding Amount
$81,143.00
Summary
Bronchiectasis is a chronic disease of the lungs which affects at least 1 in 68 NT Indigenous children. It causes recurring lung infections, hospitalisations and deteriorating lung function. This study will provide important data on the immune response of Indigenous children to NTHi, the most important pathogen associated with chronic respiratory infections and why this immune response is not protective. This is the first step in targeting therapies to the prevention of bronchiectasis.
Successful establishment of pregnancy requires a viable embryo and a receptive uterus. The contribution that reduced uterine receptivity makes to human infertility is unknown. IVF patients with implantation failure will be investigated using different approaches to identify gene pathways that are altered in reduced uterine receptivity. This study could lead to a clinical test for uterine receptivity and help to improve fertility treatment options for women with repeated implantation failure.
The Use Of Real-World Evidence To Support Regulatory And Reimbursement Decisions
Funder
National Health and Medical Research Council
Funding Amount
$91,538.00
Summary
Traditionally, medicines are studied extensively in clinical trials before they are widely available. More recently, some medicines have been allowed to enter the market without complete data on their benefits and risks. This means that these issues can only be studied once a medicine is on the market and used in routine clinical practice; this is referred to as real-world evidence. This research evaluates if this evidence is sufficient to prove that a medicine is safe and that it works
Lung cancer is the commonest cause of cancer death worldwide. There is growing interest in the genetic causes of lung cancer. The overall aim of this research is to gain a better understanding of the steps in the genetic pathway of lung cancer spread. This knowledge is essential in the development of new targeted therapies and improvement in lung cancer prognosis.
Dietary Therapies For The Treatment Of Drug-resistant Epilepsy
Funder
National Health and Medical Research Council
Funding Amount
$69,757.00
Summary
Epilepsy affects about 225,000 Australians, with 30% of suffers still experiencing seizures despite being on medications. A reduction in seizures can significantly improve the health of people with epilepsy who do not respond to medications. Low carbohydrate, high fat diets are a well-established treatment option in children, but this has not previously been studied in Australian adults. The aim of this research is to evaluate if dietary therapies are an effective treatment in adult epilepsy.